Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moonshot antibodies
- Development stage
- Phase 1
- Lead developer
- Moonshot Antibodies
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
"Moonshot antibodies" is an investigational personalized chimeric antibody therapy developed by Moonshot Antibodies. It is designed to treat Stage IV cancer patients by targeting specific mutated cell surface proteins found on their cancer cells. The antibodies are custom-made in a laboratory from each subject's tumor and blood samples, ensuring they are specific to the individual's cancer. The therapy aims to enable the body to identify and destroy these cancer cells.
02
Targets
Neoantigen (Patient-specific mutated cell surface protein)
Beyond the preview
Go deeper on Moonshot antibodies.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Moonshot antibodies.